Related Experiment Video
Updated: May 17, 2025

13:25
Transient Transduction of the Strobilated Forms of Echinococcus granulosus
Published on: September 16, 2022
2.9K
Current Management of Pulmonary Hydatid Cyst
Yener Aydın1, Ulaş Ali Bilal1, Ayşenur Dostbil2
1Department of Thoracic Surgery, Atatürk University Faculty of Medicine, Erzurum, Türkiye.
The Eurasian Journal of Medicine
|May 16, 2025
Summary
Pulmonary hydatid disease, caused by Echinococcus granulosus, affects the lungs secondarily. Surgery is the primary treatment for lung hydatid cysts, with medical therapy used adjunctively.
Area of Science:
- Medical Parasitology
- Thoracic Surgery
- Infectious Diseases
Background:
- Hydatid disease is a zoonotic infection caused by Echinococcus granulosus.
- Pulmonary involvement is the second most common site affected by hydatid cysts in both children and adults.
- Cyst growth is more rapid in children, and the disease is more prevalent in this age group.
Purpose of the Study:
- To review the diagnosis and management of pulmonary hydatid cysts.
- To highlight surgical considerations and medical treatment protocols.
Main Methods:
- Review of clinical and radiological diagnostic methods for hydatid cysts.
- Discussion of surgical techniques for pulmonary hydatid cyst removal.
- Analysis of the role of albendazole in treatment and prevention of recurrence.
Main Results:
- Uncomplicated hydatid cysts are clinically and radiologically straightforward to diagnose.
- Complicated cysts present diagnostic challenges.
- Surgical treatment is promptly planned, with cystotomy and capitonnage being the preferred method to preserve lung parenchyma.
Conclusions:
- Surgical intervention is the definitive treatment for pulmonary hydatid cysts.
- Albendazole is indicated for preventing recurrence post-surgery or when surgery is not feasible.
- Preoperative albendazole is contraindicated for intact cysts due to rupture risk.
Related Concept Videos
Pulmonary Tuberculosis V
157
Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
157
Cystic Fibrosis: Management
117
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
117
Pleural Effusion II: Symptoms and Management
137
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
137
Pneumothorax-II
110
Pneumothorax is a medical condition defined by the buildup of air in the pleural space between the lungs and the chest wall. This accumulation of air can lead to partial or complete lung collapse, resulting in a range of clinical manifestations. Understanding the clinical presentation and effective management strategies is crucial for healthcare professionals in providing timely and appropriate care to individuals with pneumothorax.
Clinical Manifestations:
Clinical Manifestations:
110
Pneumonia V: Nursing management and Prevention
1.7K
Nursing management of pneumonia involves promoting airway patency, facilitating rest and conserving energy, encouraging fluid intake, maintaining nutrition, and educating patients.
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
The nurse must practice strict medical asepsis and adhere to infection control guidelines to minimize healthcare-associated infections.
Enhance airway patency
Position the patient correctly to facilitate drainage of the affected lung segments. Manual or mechanical percussion and vibration can also be employed....
1.7K
Pneumonia IV: Management
271
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
271

